LEBRIKIZUMAB

UNII:	U9JLP7V031
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	LEBRIKIZUMAB
GSRS Full Record:	U9JLP7V031 i

953400-68-5
EBGLYSS
IMMUNOGLOBULIN G4, ANTI-(HUMAN INTERLEUKIN 13) (HUMAN-MOUSE MONOCLONAL MILR1444A .GAMMA.4-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL MILR1444A .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G4, ANTI-(HUMAN INTERLEUKIN-13); HUMANIZED MOUSE MONOCLONAL MILR1444A (226-PROLINE(H(SUP 10)S>P)).GAMMA.4 HEAVY CHAIN (132-218')-DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL MILR1444A .KAPPA. LIGHT CHAIN, DIMER (224-224'':227-227'')-BISDISULFIDE
LEBRIKIZUMAB [JAN]
LEBRIKIZUMAB [USAN]
Lebrikizumab [MI]
Lebrikizumab [WHO-DD]
Lebrikizumab lbkz [WHO-DD]
Lebrikizumab-LBKZ
MILR-1444A
MILR1444A
PRO-301444
PRO301444
RG-3637
RO-5490255
TNX-650
lebrikizumab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LEBRIKIZUMAB

Synonyms and Mappings

Resources